Visual Impairment News and Research RSS Feed - Visual Impairment News and Research

The definition of vision impairment by the Centers for Disease Control and Prevention (CDC) says a visually impaired person’s eyesight cannot be corrected to a “normal level”.
Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10. [More]
WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030. [More]
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. [More]
OIB Program helps older Californians with blindness to live and work independently

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma. [More]
Many MEN1 tumour types found in children

Many MEN1 tumour types found in children

Most tumour types reported in adult patients with multiple endocrine neoplasia Type-1 can be found in children with the condition, although rarely before the age of 10 years, shows a large study. [More]
Tackling preventable blindness: a House of Commons reception review

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International. [More]

Scientists explore how the brain adapts to visual restoration

Recent scientific advances have meant that eyesight can be partially restored to those who previously would have been blind for life. However, scientists at the University of Montreal and the University of Trento have discovered that the rewiring of the senses that occurs in the brains of the long-term blind means that visual restoration may never be complete. [More]

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
New study describes revolutionary novel device that has potential to treat eye diseases

New study describes revolutionary novel device that has potential to treat eye diseases

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration. [More]
Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). [More]
HIV drugs could be harnessed to treat leading cause of blindness

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure. [More]
Adults diagnosed with retinoblastoma as infants perform better on tasks, study finds

Adults diagnosed with retinoblastoma as infants perform better on tasks, study finds

Most long-term survivors of retinoblastoma, particularly those who had been diagnosed with tumors by their first birthdays, have normal cognitive function as adults, according to a St. Jude Children's Research Hospital study. The research, which appears in the current issue of the journal Cancer, found that the vast majority of survivors work full time, live independently and fulfill other milestones of adult life. [More]
Prosthetic retina could help counter the effects of AMD and related vision disorders

Prosthetic retina could help counter the effects of AMD and related vision disorders

The loss of eyesight, often caused by retinal degeneration, is a life-altering health issue for many people, especially as they age. [More]
Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London. [More]
Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies. [More]
VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. [More]
Advertisement
Advertisement